RU2020137384A - Средство для лечения опухоли и набор, содержащий липосомальную композицию гемцитабина - Google Patents
Средство для лечения опухоли и набор, содержащий липосомальную композицию гемцитабина Download PDFInfo
- Publication number
- RU2020137384A RU2020137384A RU2020137384A RU2020137384A RU2020137384A RU 2020137384 A RU2020137384 A RU 2020137384A RU 2020137384 A RU2020137384 A RU 2020137384A RU 2020137384 A RU2020137384 A RU 2020137384A RU 2020137384 A RU2020137384 A RU 2020137384A
- Authority
- RU
- Russia
- Prior art keywords
- liposome
- liposomal composition
- mol
- composition according
- paragraphs
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dispersion Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Claims (9)
1. Липосомальная композиция, в которой гемцитабин или его соль содержится в липосоме,
где отношение содержания холестеринов к общему количеству липидов, образующих липосому, составляет от 10 мол.% до 35 мол.%, и
где осмотическое давление внутренней водной фазы липосомы составляет от 2 до 8 раз осмотического давления внешней водной фазы липосомы, и
где липосомальная композиция представляет собой противоопухолевое терапевтическое средство.
2. Липосомальная композиция по п. 1, где липосомой является одиночная пластинка.
3. Липосомальная композиция по п. 1 или 2, где скорость высвобождения гемцитабина или его соли из липосомальной композиции в плазме составляет от 10 мас.%/24 ч до 70 мас.%/24 ч.
4. Липосомальная композиция по любому из пп. 1-3, где липид, образующий липосомы, содержит гидрогенизированный соевый фосфатидилхолин, 1,2-дистеароил-3-фосфатидилэтаноламинполиэтиленгликоль и холестерин.
5. Липосомальная композиция по любому из пп. 1-4, где средний диаметр частиц липосомы составляет от 2 нм до 200 нм.
6. Липосомальная композиция по любому из пп. 1-5, где отношение содержания холестеринов к общему количеству липидов, образующих липосому, составляет от 17 мол.% до 21 мол.%.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2015-215768 | 2015-11-02 | ||
| JP2015215768 | 2015-11-02 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2018119680A Division RU2738365C2 (ru) | 2015-11-02 | 2016-11-01 | Средство для лечения опухоли и набор, содержащий липосомальную композицию гемцитабина |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| RU2020137384A true RU2020137384A (ru) | 2020-12-03 |
| RU2020137384A3 RU2020137384A3 (ru) | 2021-03-31 |
| RU2761620C2 RU2761620C2 (ru) | 2021-12-13 |
Family
ID=58662534
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2018119680A RU2738365C2 (ru) | 2015-11-02 | 2016-11-01 | Средство для лечения опухоли и набор, содержащий липосомальную композицию гемцитабина |
| RU2020137385A RU2768178C2 (ru) | 2015-11-02 | 2016-11-01 | Средство для лечения опухоли и набор, содержащий липосомальную композицию гемцитабина |
| RU2020137384A RU2761620C2 (ru) | 2015-11-02 | 2016-11-01 | Средство для лечения опухоли и набор, содержащий липосомальную композицию гемцитабина |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2018119680A RU2738365C2 (ru) | 2015-11-02 | 2016-11-01 | Средство для лечения опухоли и набор, содержащий липосомальную композицию гемцитабина |
| RU2020137385A RU2768178C2 (ru) | 2015-11-02 | 2016-11-01 | Средство для лечения опухоли и набор, содержащий липосомальную композицию гемцитабина |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US11166913B2 (ru) |
| EP (1) | EP3372232B1 (ru) |
| JP (1) | JP6602886B2 (ru) |
| KR (1) | KR102084340B1 (ru) |
| CN (3) | CN111437259A (ru) |
| DK (1) | DK3372232T3 (ru) |
| ES (1) | ES2869283T3 (ru) |
| MA (1) | MA43183A (ru) |
| PL (1) | PL3372232T3 (ru) |
| RU (3) | RU2738365C2 (ru) |
| WO (1) | WO2017078008A1 (ru) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT3138555T (pt) | 2014-04-30 | 2020-12-15 | Fujifilm Corp | Composição lipossómica e método de produção da mesma |
| DK3372232T3 (da) | 2015-11-02 | 2021-06-07 | Fujifilm Corp | Tumorterapeutisk middel omfattende gemcitabinliposomsammensætning og kit |
| CN114224840A (zh) | 2017-03-31 | 2022-03-25 | 富士胶片株式会社 | 脂质体组合物及医药组合物 |
| JP7036919B2 (ja) * | 2018-06-20 | 2022-03-15 | 富士フイルム株式会社 | 薬物を内包するリポソーム組成物および免疫チェックポイント阻害剤を含む組合せ医薬 |
| CN112334140A (zh) * | 2018-06-20 | 2021-02-05 | 富士胶片株式会社 | 包含内含吉西他滨的脂质体组合物及免疫检查点抑制剂的组合医药 |
| EP3861987A4 (en) * | 2018-10-01 | 2021-09-15 | FUJIFILM Corporation | COMBINATION DRUG CONTAINING A LIPOSOME COMPOSITION ENCAPSULATING A DRUG AND A PLATINUM PREPARATION |
| CN112898277B (zh) * | 2019-11-19 | 2022-04-22 | 扬子江药业集团有限公司 | 一种阿法替尼中间体的制备方法 |
| CN111035616B (zh) * | 2019-12-30 | 2022-03-22 | 上海景峰制药有限公司 | 一种吉西他滨脂质体及其制备方法和应用 |
| JP2021181426A (ja) * | 2020-04-03 | 2021-11-25 | 富士フイルム株式会社 | 抗腫瘍剤 |
| WO2023179423A1 (zh) * | 2022-03-25 | 2023-09-28 | 四川科伦药物研究院有限公司 | 一种吉西他滨脂质体药物组合物及其制备方法和应用 |
| WO2023186923A1 (en) | 2022-03-30 | 2023-10-05 | Meta Materials Inc. | Implanted agent delivery system |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5049392A (en) * | 1989-01-18 | 1991-09-17 | The Liposome Company, Inc. | Osmotically dependent vesicles |
| WO2004017944A1 (en) * | 2002-08-23 | 2004-03-04 | Neopharm, Inc. | Liposomal gemcitabine compositions for better drug delivery |
| EP1643971A2 (en) * | 2003-05-22 | 2006-04-12 | Neopharm, Inc. | Liposomal formulations comprising a combination of two or more active agents |
| WO2005021012A1 (ja) * | 2003-08-29 | 2005-03-10 | Terumo Kabushiki Kaisha | ゲムシタビン封入薬剤担体 |
| CA2821167C (en) | 2004-05-03 | 2016-06-28 | Merrimack Pharmaceuticals, Inc. | Drug delivery liposomes containing anionic polyols or anionic sugars |
| WO2007005754A2 (en) * | 2005-07-01 | 2007-01-11 | Alza Corporation | Liposomal delivery vehicle for hydrophobic drugs |
| WO2007067784A2 (en) * | 2005-12-08 | 2007-06-14 | Wyeth | Liposomal compositions |
| US8119156B2 (en) * | 2006-10-24 | 2012-02-21 | Aradigm Corporation | Dual action, inhaled formulations providing both an immediate and sustained release profile |
| CN101209243B (zh) | 2006-12-29 | 2010-12-08 | 石药集团中奇制药技术（石家庄）有限公司 | 一种脂质体药物及其制备方法 |
| CN100496609C (zh) * | 2006-12-30 | 2009-06-10 | 上海艾力斯医药科技有限公司 | 一种稳定的脂质体组合物 |
| AU2008268566A1 (en) * | 2007-06-22 | 2008-12-31 | Innovative Surface Technologies, Inc. | Stimuli responsive nanofibers |
| WO2009040426A1 (en) * | 2007-09-28 | 2009-04-02 | Universitätsspital Basel | Immunoliposomes for treatment of cancer |
| US8079820B2 (en) * | 2008-12-18 | 2011-12-20 | General Electric Company | Blade module, a modular rotor blade and a method for assembling a modular rotor blade |
| EP2394640A1 (en) * | 2010-05-21 | 2011-12-14 | MediGene AG | Improved liposomal formulations of lipophilic compounds |
| BR112013024663A2 (pt) * | 2011-03-25 | 2016-12-20 | Terumo Corp | composição de lipossomas de liberação controlada de longa duração e método para produção da mesma |
| US8987224B2 (en) * | 2011-08-05 | 2015-03-24 | Baylor College Of Medicine | MicroRNA-198 as a tumor suppressor in pancreatic cancer |
| US9370489B2 (en) * | 2011-10-31 | 2016-06-21 | Mallinckrodt Llc | Combinational liposome compositions for cancer therapy |
| EP2604253A1 (en) * | 2011-12-13 | 2013-06-19 | Otto Glatter | Water-in-oil emulsions and methods for their preparation |
| WO2013151774A1 (en) * | 2012-04-04 | 2013-10-10 | Halozyme, Inc. | Combination therapy with an anti - hyaluronan agent and a tumor - targeted taxane |
| CN102784107B (zh) * | 2012-05-17 | 2015-04-22 | 江苏豪森药业股份有限公司 | 一种吉西他滨或其盐脂质体及其制备方法和用途 |
| WO2014092858A1 (en) * | 2012-12-12 | 2014-06-19 | Temple University - Of The Commonwealth System Of Higher Education | Compositions and methods for treatment of cancer |
| US9968570B2 (en) | 2013-01-14 | 2018-05-15 | Chemo-Enhanced Llc | Compositions and methods for treating cancer |
| WO2014138278A1 (en) | 2013-03-05 | 2014-09-12 | The Regents Of The University Of California | Lipid bilayer coated mesoporous silica nanoparticles with a high loading capacity for one or more anticancer agents |
| WO2015166985A1 (ja) * | 2014-04-30 | 2015-11-05 | 富士フイルム株式会社 | リポソーム組成物及びその製造方法 |
| JP6276847B2 (ja) | 2014-04-30 | 2018-02-07 | 富士フイルム株式会社 | リポソーム組成物及びその製造方法 |
| DK3372232T3 (da) | 2015-11-02 | 2021-06-07 | Fujifilm Corp | Tumorterapeutisk middel omfattende gemcitabinliposomsammensætning og kit |
| WO2017192863A1 (en) * | 2016-05-04 | 2017-11-09 | L.E.A.F. Holdings Group Llc | Targeted liposomal gemcitabine compositions and methods thereof |
-
2016
- 2016-11-01 DK DK16862068.0T patent/DK3372232T3/da active
- 2016-11-01 RU RU2018119680A patent/RU2738365C2/ru active
- 2016-11-01 CN CN202010466486.3A patent/CN111437259A/zh active Pending
- 2016-11-01 JP JP2017548769A patent/JP6602886B2/ja active Active
- 2016-11-01 CN CN202010466892.XA patent/CN111632030B/zh active Active
- 2016-11-01 MA MA043183A patent/MA43183A/fr unknown
- 2016-11-01 PL PL16862068T patent/PL3372232T3/pl unknown
- 2016-11-01 CN CN201680064060.7A patent/CN108348538B/zh active Active
- 2016-11-01 KR KR1020187012568A patent/KR102084340B1/ko active IP Right Grant
- 2016-11-01 RU RU2020137385A patent/RU2768178C2/ru active
- 2016-11-01 EP EP16862068.0A patent/EP3372232B1/en active Active
- 2016-11-01 WO PCT/JP2016/082415 patent/WO2017078008A1/ja active Application Filing
- 2016-11-01 ES ES16862068T patent/ES2869283T3/es active Active
- 2016-11-01 RU RU2020137384A patent/RU2761620C2/ru active
-
2018
- 2018-05-01 US US15/967,970 patent/US11166913B2/en active Active
-
2020
- 2020-03-03 US US16/808,004 patent/US11166914B2/en active Active
-
2021
- 2021-02-25 US US17/184,928 patent/US20210275453A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| RU2018119680A (ru) | 2019-12-05 |
| ES2869283T3 (es) | 2021-10-25 |
| RU2761620C2 (ru) | 2021-12-13 |
| RU2768178C2 (ru) | 2022-03-23 |
| RU2020137384A3 (ru) | 2021-03-31 |
| KR20180054873A (ko) | 2018-05-24 |
| US20200197305A1 (en) | 2020-06-25 |
| PL3372232T3 (pl) | 2021-09-27 |
| CN111632030B (zh) | 2023-01-17 |
| CN108348538A (zh) | 2018-07-31 |
| EP3372232A4 (en) | 2018-11-14 |
| MA43183A (fr) | 2018-09-12 |
| US20210275453A1 (en) | 2021-09-09 |
| DK3372232T3 (da) | 2021-06-07 |
| RU2020137385A (ru) | 2020-12-03 |
| CN111437259A (zh) | 2020-07-24 |
| CN108348538B (zh) | 2021-06-22 |
| EP3372232B1 (en) | 2021-04-14 |
| JPWO2017078008A1 (ja) | 2018-08-09 |
| US11166913B2 (en) | 2021-11-09 |
| RU2738365C2 (ru) | 2020-12-11 |
| WO2017078008A1 (ja) | 2017-05-11 |
| CN111632030A (zh) | 2020-09-08 |
| JP6602886B2 (ja) | 2019-11-06 |
| US11166914B2 (en) | 2021-11-09 |
| RU2020137385A3 (ru) | 2021-03-31 |
| RU2018119680A3 (ru) | 2019-12-05 |
| KR102084340B1 (ko) | 2020-03-03 |
| US20180243214A1 (en) | 2018-08-30 |
| EP3372232A1 (en) | 2018-09-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2020137384A (ru) | Средство для лечения опухоли и набор, содержащий липосомальную композицию гемцитабина | |
| WO2015184256A3 (en) | Biodegradable lipids for delivery of nucleic acids | |
| WO2019036008A8 (en) | Lipids for use in lipid nanoparticle formulations | |
| AU2016343803A8 (en) | Novel lipids and lipid nanoparticle formulations for delivery of nucleic acids | |
| BR112015022476A2 (pt) | composições de oxaliplatina de lipossoma para terapia de câncer | |
| NZ732777A (en) | Ionizable cationic lipid for rna delivery | |
| GT201600050A (es) | Nanopartículas poliméricas terapéuticas y métodos para su elaboración y uso | |
| WO2014172045A8 (en) | Lipid nanoparticles for transfection and related methods | |
| MX2015012201A (es) | Formulaciones modificadas de liposomas de docetaxel. | |
| IN2014DN05866A (ru) | ||
| WO2015184127A3 (en) | Stable cannabinoid formulations | |
| CA2868034C (en) | Ionizable cationic lipids | |
| MX2015012199A (es) | Composiciones de cisplatino liposomal para la terapia contra el cancer. | |
| GB2541835A (en) | Multivesicular liposome formulations of tranexamic acid | |
| WO2012154942A3 (en) | Ceramide anionic liposome compositions | |
| WO2016040887A3 (en) | Multilamellar lipid vesicle compositions and methods of use | |
| WO2012053009A3 (en) | Pharmaceutical compositions comprising nano size droplets of skin whitening agents | |
| WO2016087649A3 (en) | Use of cannabinoids as ceramide-generating anticancer agents in tumors of the hematopoietic and lymphoid tissues | |
| RU2016112257A (ru) | Композиция для лечения гипертензии и/или фиброза | |
| WO2019108021A3 (ko) | 토파시티닙을 포함하는 약제학적 조성물 | |
| WO2014167435A3 (en) | Liposomal pharmaceutical formulations for enhanced drug delivery | |
| JP2015511618A5 (ru) | ||
| PH12014502836B1 (en) | Medicament form for release of active ingredients | |
| MX2017009659A (es) | Composiciones que contienen arsenico y su uso en metodos de tratamiento. | |
| BR112013027685A2 (pt) | composição oral líquida compreendendo divalproex sódico e processo de preparação do mesmo |